EPO and anemia (phenotype): In a post hoc analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) Trial, which compared the use of erythropoietin versus a placebo in 4038 patients, with T2D-associated CKD and anaemia, followed up for 29.1 months, metformin was associated with lower risk of ESKD in eGFR-G1/G3 (HR = 0.70, 0.53–0.92), but neutral risk in eGFR-G4/G5 (HR = 0.95, 0.70–1.29) [12].